Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 dose-escalation study of subcutaneous ELX-02 in cystic fibrosis with at least one G542X allele
MOH_2019-09-19_007408Phase 2Not yet recruiting
- Sponsor
- Eloxx Pharmaceuticals
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of exaluren in cystic fibrosis (CF), sponsored by Eloxx Pharmaceuticals. Primary endpoint: Safety and tolerability of multiple ascending doses of ELX-02. Planned start Jul 2019; status: not yet recruiting.
02
Drugs
exaluren
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on MOH_2019-09-19_007408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-09-19_007408.